10 Best IPO Stocks To Buy Heading into 2025

3. Apogee Therapeutics Inc. (NASDAQ:APGE)

Average Upside Potential: 57.81%

Number of Hedge Fund Holders: 30

Apogee Therapeutics Inc. (NASDAQ:APGE) is a clinical-stage biotechnology company advancing differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), asthma, and other inflammatory and immune (I&I) diseases with high unmet need among patients.

The company’s flagship program, APG777, is specifically focused on atopic dermatitis, a significant and underserved market. With a portfolio of 4 promising targets, Apogee Therapeutics Inc. (NASDAQ:APGE) aims to enhance treatment efficacy and dosing by utilizing both single therapies and combination antibody approaches. In H2 2025, it plans to release 16-week proof-of-concept data for APG777. Additionally, interim Phase 1 data for APG808, a novel IL-4Rα antibody targeting COPD, is anticipated in Q4 2024.

The company is set to initiate the APG990 trial in the third quarter of 2024, targeting atopic dermatitis and other inflammatory diseases. Furthermore, Apogee has expanded its portfolio with APG333, a novel antibody targeting TSLP to address respiratory conditions. Clinical trials for APG333 are expected to commence in 2025. With a robust cash position of $790 million, Apogee is well-positioned to fund operations through 2028.

The recent FDA approval of Dupixent for COPD with eosinophilic phenotype has reduced the risk associated with developing APG808, as both treatments target a similar patient population, demonstrating the growing acceptance of biologic therapies in the COPD market. Additionally, the positive results from the Phase 1 trials of APG777 further bolster this perspective. The modifications incorporated into APG777 enable longer-lasting effects, potentially leading to less frequent dosing compared to existing treatments. These factors, coupled with the company’s strong financial position, position Apogee Therapeutics Inc. (NASDAQ:APGE) for significant growth and success in the future.